(a) The commission shall periodically review all purchases made under the vendor drug program to determine the cost-effectiveness of including a component for prescription drug benefits in any capitation rate paid by the state under a Medicaid managed care program or the child health plan program.
(b) In making the determination required by Subsection (a), the commission shall consider the value of any prescription drug rebates received by the state.

Text of section effective until April 01, 2025